Neumora Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Henry O. Gosebruch and Joshua Pinto, Ph.D., and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
| Name | Title | Date |
|---|---|---|
| /s/ Paul L. Berns | Chief Executive Officer | March 3, 2025 |
| Paul L. Berns | (Principal Executive Officer) | |
| /s/ Joshua Pinto, Ph.D. | President | March 3, 2025 |
| Joshua Pinto, Ph.D. | ||
| /s/ Michael Milligan | Chief Financial Officer | March 3, 2025 |
| Michael Milligan | (Principal Financial and Accounting Officer) | |
| /s/ Kristina M. Burow | Director | March 3, 2025 |
| Kristina M. Burow | ||
| /s/ Matthew K. Fust | Director | March 3, 2025 |
| Matthew K. Fust | ||
| /s/ Alaa Halawa | Director | March 3, 2025 |
| Alaa Halawa | ||
| /s/ Maykin Ho, Ph.D. | Director | March 3, 2025 |
| Maykin Ho, Ph.D. | ||
| /s/ David Piacquad | Director | March 3, 2025 |
| David Piacquad | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.